Pipeline
11-19-2008 |
15:23 hs.
Novartis AG said biological drugs represent some 25 percent of the exploratory pipeline, as their product portfolio increased 40 percent since 2005. The company revealed that it has a total of 139 compounds in clinical trials. Further details.
11-10-2008 |
13:42 hs.
Not a cost reduction, says company
10-29-2008 |
08:46 hs.
Wyeth confirmed its current overall strategy is to concentrate its early-stage research to a half-dozen therapeutic areas, continue to conduct research on drugs already in development and selling their existing products. Further details.
Obesity, heart disease, digestive disorders: unprofitable
09-30-2008 |
12:02 hs.
Pfizer Inc announced in a memo to employees that it is ending early-stage development of treatments for a range of illnesses from obesity to heart disease, in order to focus on more ‘profitable diseases’. CEO Jeffrey Kindler has stated previously that the company would be investing in products for cancer, pain, Alzheimer´s disease and diabetes. End-stage products will not be affected; neither will there be facility closures. Employees will be shifted to other areas of research.
GlaxoSmithKline´s Relenza Long-Acting Version
07-31-2008 |
13:11 hs.
Exclusive
06-09-2008 |
13:05 hs.
Below, a comprehensive list of AstraZeneca’s drug development pipeline (Phase I, Phase II, and Phase III)
Exclusive
06-09-2008 |
13:03 hs.
Below, a comprehensive list of GlaxoSmithKline Plc’s drug development pipeline (Phase I, Phase II, and Phase III)
With experimental Sutent, Axitinib and CP-751871
06-03-2008 |
13:02 hs.
In the framework of the American Society of Clinical Oncology (ASCO) meeting, giant drugmaker Pfizer Inc. announced it expects to start seven Phase 3 studies in oncology in 2008, two for which the company is already enrolling. The trials involve three compounds. Further details.
05-08-2008 |
12:21 hs.
Roche’s portfolio of blockbuster cancer drugs has been fueling the Swiss company’s earnings by more than 20 percent a year since 2004. But the drugmaker is now looking ahead: it seeks to expand its target market and break into the $21 billion-a-year diabetes market
04-14-2008 |
10:58 hs.
Eli Lilly’s R&D pipeline and its development status: Phase I, II, and III clinical trials
04-14-2008 |
10:49 hs.
A comprehensive list of Bristol-Myers Squibb’s R&D pipeline and its development status: Phase I, II, and III clinical trials
04-14-2008 |
10:45 hs.
A comprehensive list of Whitehouse Station, New Jersey-based pharmaceutical giant Merck& Co’s R&D pipeline and its development status: Phase I, II, and III clinical trials
New Boehringer drugs: blood thinner Pradaxa & Ectris, a sex drug for w
04-08-2008 |
14:27 hs.
Boehringer Ingelheim’s massive development pipeline will drive its sales growth as Germany’s drugmaker prepares to launch new drugs worth approximately $3.9 billion over the next years. Leading rivals struggle to revamp their dwindling pipelines. Full story
03-06-2008 |
19:36 hs.
03-06-2008 |
19:31 hs.
03-06-2008 |
19:29 hs.
Forecasts Point to 30-some Phase III Studies and 15-20 Regulatory Subm
03-06-2008 |
11:01 hs.
In a meeting with market analysts in New York, Pfizer Inc. unveiled a forecast on its plans through 2012, in moves that pointed to an attempt to offset the patent loss of its blockbuster statin Lipitor and other patented drugs between 2010 and 2012. Although Pfizer will be focusing its R&D on “high-value” areas such as oncology, diabetes and schizophrenia, analysts believe the new products will not get to replace Lipitor’s selling power. Full story.
TG 4010, en Fase IIb
01-12-2008 |
12:30 hs.
La biotecnológica francesa Transgene Therapeutic presentó datos preliminares positivos de un testeo en Fase IIb clínica realizada para su vacuna terapéutica TG 4010, en el tratamiento como adyuvante en la primera línea de tratamiento de pacientes con cáncer en células no pequeñas del pulmón. Los datos completos del estudio serán presentados en el último trimestre del año. Detalles.
